Table 1.
Biographical, histological, surgical, and medical information for enrolled breast cancer patients.
| Demographic and clinical information for breast cancer patients (n = 23) | ||
|---|---|---|
| Age, median (range) | 70 (40–83) | |
| Sex, n (%) | 2 (8.70%) | Male |
| 21 (91.30%) | Female | |
| Cancer typea, n (%) | 16 (69.57%) | Ductal invasive |
| 5 (21.74%) | Lobular invasive | |
| 2 (8.70%) | Invasive solid papillary carcinoma | |
| 1 (4.35%) | Metastatic spindle cell carcinoma | |
| Tumour grade, n (%) | 16 (69.57%) | Grade 2 |
| 7 (30.43%) | Grade 3 | |
| Surgery type, n (%) | 15 (65.22%) | Mastectomy |
| 8 (34.78%) | Wide local excision | |
| Tumour size in cm, median (range) | 3 (0.2–10) | |
| Largest metastatic focus in cm, median (range) | 1.1 (0.1–3) | |
| Antibiotic use within 1 month prior to surgeryb, n (%) | 2 (8.70%) | |
| Regular probiotic useb, n (%) | 11 (47.83%) | |
| History of breastfeedingb, n (%) | 6 (26.09%) | |
| History of adjuvant therapy, n (%) | 0 (0%) | |
| History of neoadjuvant therapy, n (%) | 1 (4.35%) | |
| Tumour necrosis, n (%) | 9 (39.13%) | |
| Calcifications—malignancy-associated, n (%) | 8 (34.78%) | |
| Calcifications—benign tissue-associated, n (%) | 11 (47.83%) | |
| Oestrogen receptor positive, n (%) | 21 (91.30%) | |
| Progesterone receptor positive, n (%) | 18 (78.26%) | |
| HER-2 receptor positive, n (%) | 0 (0%) | |
| Ductal ectasia, n (%) | 3 (13.04%) | |
| Focal lactational change, n (%) | 1 (4.35%) | |
| Lymphovascular invasion, n (%) | 12 (52.17%) | |
| Extranodal extension, n (%) | 9 (39.13%) | |
| Extensive intraductal component, n (%) | 1 (4.35%) | |
| Skin involvement, n (%) | 8 (34.78%) | |
aSome patients had overlapping cancer types (e.g., both lobular carcinoma and ductal invasive carcinoma).
bOne patient did not provide information.